廣告
香港股市 已收市

  • 恒指

    17,651.15
    +366.61 (+2.12%)
     

  • 國指

    6,269.76
    +149.39 (+2.44%)
     

  • 上證綜指

    3,088.64
    +35.74 (+1.17%)
     

  • 滬深300

    3,584.27
    +53.99 (+1.53%)
     

  • 美元

    7.8282
    +0.0004 (+0.01%)
     

  • 人民幣

    0.9252
    +0.0009 (+0.10%)
     

  • 道指

    38,208.26
    +122.46 (+0.32%)
     

  • 標普 500

    5,104.70
    +56.28 (+1.11%)
     

  • 納指

    15,943.79
    +332.04 (+2.13%)
     

  • 日圓

    0.0495
    -0.0005 (-1.08%)
     

  • 歐元

    8.3622
    -0.0360 (-0.43%)
     

  • 英鎊

    9.7510
    -0.0410 (-0.42%)
     

  • 紐約期油

    83.43
    -0.14 (-0.17%)
     

  • 金價

    2,343.90
    +1.40 (+0.06%)
     

  • Bitcoin

    63,815.31
    +496.98 (+0.78%)
     

  • CMC Crypto 200

    1,331.55
    -64.98 (-4.65%)
     

Poseida Shares Rally As Roche Takes Next Big Step Into Allogeneic CAR-T Field

Vandana Singh
·1 分鐘文章

  • Poseida Therapeutics Inc (NASDAQ: PSTX) has entered into a strategic collaboration and license agreement with Roche Holdings AG (OTC: RHHBY), focused on developing allogeneic CAR-T therapies directed to hematologic malignancies.

  • The collaboration covers the research and development of multiple existing and novel "off-the-shelf" cell therapies against targets in multiple myeloma, B-cell lymphomas, and other hematologic indications.

  • Under the agreement, Roche will receive from Poseida either exclusive rights or options to develop and commercialize several allogeneic CAR-T programs in Poseida's portfolio.

  • Poseida's P-BCMA-ALLO1, an allogeneic CAR-T for multiple myeloma, is in Phase 1 study, and P-CD19CD20-ALLO1, an allogeneic dual CAR-T for B-cell malignancies with an IND, expected in 2023.

  • For a subset of the Poseida portfolio programs licensed or optioned to Roche, Poseida will conduct the Phase 1 studies and manufacture clinical materials before transitioning the programs to Roche for further development and commercialization.

  • Roche will be solely responsible for the late-stage clinical development and global commercialization.

  • Poseida will receive $110 million upfront and could receive up to $110 million in near-term milestones.

  • In addition, Poseida is eligible to receive up to $6 billion in milestone payments.

  • Price Action: PSTX shares are up 60.10% at $3.89 during the premarket session on the last check Wednesday.

See more from Benzinga

廣告

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.